
iECURE to Present Full Data for First Infant Dosed with ECUR-506 in OTC-HOPE Trial at 2025 ACMG Annual Meeting
iECURE Presents Promising Data for ECUR-506 in OTC-HOPE Phase 1/2 Trial at 2025 ACMG Annual Meeting iECURE, Inc., a gene editing company focused on developing mutation-agnostic in vivo gene insertion therapies for liver disorders, has shared encouraging results from the…